CORRInsights®: What Factors Are Associated With Failure of Compressive Osseointegration Fixation?

    loading  Checking for direct PDF access through Ovid


The current generation of skeletal osseointegration implants for oncologic indications can be traced back to the clearance of the Compress® (Biomet, Warsaw, IN, USA) implant by the FDA in December 2003 [7]. Since then, numerous papers have attested to its durability and reliability for diaphyseal bone fixation [2, 6, 8, 10].
In the current study, Kagan and colleagues extended our knowledge of this implant design by searching for patterns of implant failure. In their largest retrospective series to date, the authors reviewed 116 implants and found that the anatomic location of the implant predicted survival of their reconstructions. Additionally, neither the age of the patient nor chemotherapy were associated with differences in implant survival. The most common reason for failure was infection. These findings are in line with other recent oncologic series of cemented diaphyseal fixation [4].
    loading  Loading Related Articles